BACKGROUND: Gene expression profiling has successfully identified the prognostic significance of the host response in lymphomas. The aggressive T-cell/histiocyte-rich large B-cell lymphoma and the indolent nodular lymphocyte-predominant Hodgkin's lymphoma are both characterized by a paucity of tumor cells embedded in an overwhelming background. The tumor cells of both lymphomas share several characteristics, while the cellular composition of their microenvironment is clearly different. DESIGN AND METHODS: We collected 33 cases of T-cell/histiocyte-rich large B-cell lymphoma and 56 cases of nodular lymphocyte-predominant Hodgkin's lymphoma and performed microarray gene expression profiling on ten cases of each lymphoma, to obtain a better understanding of the lymphoma host response. By quantitative reverse transcriptase polymerase chain reaction we verified that these 20 selected cases were representative of the entire population of T-cell/histiocyte-rich large B-cell and nodular lymphocyte-predominant Hodgkin's lymphomas. RESULTS: We observed that the microenvironment in nodular lymphocyte-predominant Hodgkin's lymphoma is molecularly very similar to a lymph node characterized by follicular hyperplasia, while the microenvironment in T-cell/histiocyte-rich large B-cell lymphoma is clearly different. The T-cell/histiocyte-rich large B-cell lymphoma signature is hallmarked by up-regulation of CCL8, interferon-gamma, indoleamine 2,3 dioxygenase, VSIG4 and Toll-like receptors. These features may be responsible for the recruitment and activation of T cells, macrophages and dendritic cells, characterizing the stromal component of this lymphoma, and may point towards innate immunity and a tumor tolerogenic immune response in T-cell/histiocyte-rich large B-cell lymphoma. CONCLUSIONS: The gene expression profile of T-cell/histiocyte-rich large B-cell lymphoma, in comparison with that of nodular lymphocyte-predominant Hodgkin's lymphoma, shows features suggestive of a distinct tolerogenic host immune response that may play a key role in the aggressive behavior of this lymphoma, and that may serve as a potential target for future therapy.
BACKGROUND: Gene expression profiling has successfully identified the prognostic significance of the host response in lymphomas. The aggressive T-cell/histiocyte-rich large B-cell lymphoma and the indolent nodular lymphocyte-predominant Hodgkin's lymphoma are both characterized by a paucity of tumor cells embedded in an overwhelming background. The tumor cells of both lymphomas share several characteristics, while the cellular composition of their microenvironment is clearly different. DESIGN AND METHODS: We collected 33 cases of T-cell/histiocyte-rich large B-cell lymphoma and 56 cases of nodular lymphocyte-predominant Hodgkin's lymphoma and performed microarray gene expression profiling on ten cases of each lymphoma, to obtain a better understanding of the lymphoma host response. By quantitative reverse transcriptase polymerase chain reaction we verified that these 20 selected cases were representative of the entire population of T-cell/histiocyte-rich large B-cell and nodular lymphocyte-predominant Hodgkin's lymphomas. RESULTS: We observed that the microenvironment in nodular lymphocyte-predominant Hodgkin's lymphoma is molecularly very similar to a lymph node characterized by follicular hyperplasia, while the microenvironment in T-cell/histiocyte-rich large B-cell lymphoma is clearly different. The T-cell/histiocyte-rich large B-cell lymphoma signature is hallmarked by up-regulation of CCL8, interferon-gamma, indoleamine 2,3 dioxygenase, VSIG4 and Toll-like receptors. These features may be responsible for the recruitment and activation of T cells, macrophages and dendritic cells, characterizing the stromal component of this lymphoma, and may point towards innate immunity and a tumor tolerogenic immune response in T-cell/histiocyte-rich large B-cell lymphoma. CONCLUSIONS: The gene expression profile of T-cell/histiocyte-rich large B-cell lymphoma, in comparison with that of nodular lymphocyte-predominant Hodgkin's lymphoma, shows features suggestive of a distinct tolerogenic host immune response that may play a key role in the aggressive behavior of this lymphoma, and that may serve as a potential target for future therapy.
Authors: S Franke; I Wlodarska; B Maes; P Vandenberghe; J Delabie; A Hagemeijer; C De Wolf-Peeters Journal: Blood Date: 2001-03-15 Impact factor: 22.113
Authors: Sabine Franke; Iwona Wlodarska; Brigitte Maes; Peter Vandenberghe; Ruth Achten; Anne Hagemeijer; Chris De Wolf-Peeters Journal: Am J Pathol Date: 2002-11 Impact factor: 4.307
Authors: T Rüdiger; R D Gascoyne; E S Jaffe; D de Jong; J Delabie; C De Wolf-Peeters; S Poppema; L Xerri; C Gisselbrecht; S Wiedenmann; H K Müller-Hermelink Journal: Ann Oncol Date: 2002 Impact factor: 32.976
Authors: Megan S Lim; Michael Beaty; Lynn Sorbara; Richard Z Cheng; Stefania Pittaluga; Mark Raffeld; Elaine S Jaffe Journal: Am J Surg Pathol Date: 2002-11 Impact factor: 6.394
Authors: Daphne de Jong; Margaretha G M Roemer; John K C Chan; John Goodlad; Dita Gratzinger; Amy Chadburn; Elaine S Jaffe; Jonathan Said; Yasodha Natkunam Journal: Am J Clin Pathol Date: 2017-02-01 Impact factor: 2.493
Authors: Gabriel K Griffin; Jason L Weirather; Margaretha G M Roemer; Mikel Lipschitz; Alyssa Kelley; Pei-Hsuan Chen; Daniel Gusenleitner; Erin Jeter; Christine Pak; Evisa Gjini; Bjoern Chapuy; Michael H Rosenthal; Jie Xu; Benjamin J Chen; Aliyah R Sohani; Scott B Lovitch; Jeremy S Abramson; Jeffrey J Ishizuka; Austin I Kim; Caron A Jacobson; Ann S LaCasce; Christopher D Fletcher; Donna Neuberg; Gordon J Freeman; F Stephen Hodi; Kyle Wright; Azra H Ligon; Eric D Jacobsen; Philippe Armand; Margaret A Shipp; Scott J Rodig Journal: Blood Date: 2021-03-11 Impact factor: 22.113